Breaking News

Hitachi Chemical Acquires Remaining Stake in PCT

Expands services in the U.S. and adds services in Japan, Europe and other regions

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Hitachi Chemical Co. America, Ltd. has completed its acquisition of the remaining interest in PCT Cell Therapy Services, a CDMO for the cell therapy industry, from Caladrius Biosciences. PCT becomes an independent business unit focused on cell therapy and regenerative medicine within the life sciences division of Hitachi Chemical. Hitachi Chemical will leverage PCT’s expertise in cell therapy development and manufacturing technology, manufacturing locations, and other resources to expand its ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters